Search
for
Sort by
Research 901–930 of 1000+
- Hair shaft disorders in a child with loose anagen syndrome and uncombable hair: Clues to an underlying genetic disorder
- Topical latanoprost acid for female androgenetic alopecia: a pilot proof-of-concept trial with mechanistic evidence of prostaglandin F2α receptor activation
- A practical guide on Polyendocrine Metabolic Ovarian Syndrome (PMOS) for Clinicians
- Anti-Müllerian Hormone and Ovarian Morphology in Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS): Toward More Precise Diagnosis and Phenotype Stratification
- Quality of Life in Men Treated for Androgenetic Alopecia via a Digital Healthcare Platform: A Retrospective Cohort Study
- Topical latanoprost acid for female androgenetic alopecia: a pilot proof-of-concept trial with mechanistic evidence of FP-receptor activation
- Quality of life in men treated for androgenetic alopecia via a virtual healthcare platform: a retrospective cohort study
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- Unravelling Prevalence and Pattern of Various Hormonal Dysfunctions Among Reproductive Age Community Dwelling Indian Women: Lessons From ICMR PCOS Task Force Sub Study
- Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata
- Perspectiva cirúrgica - Um comentário sobre: “Alopecia triangular temporal bilateral simulando alopecia androgenética de padrão masculino em mulher adulta: relato de caso e revisão da literatura”
- Continued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year
- Publisher Correction: Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
- 52898 Among scalp non-responder patients with eyebrow/eyelash regrowth in the first year, continued treatment with baricitinib resulted in meaningful scalp responses for patients with severe alopecia areata
- 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
- 52874 Timing of eyebrow and eyelash regrowth among subgroups of scalp responders during treatment of severe alopecia areata with baricitinib
- Depression, higher level of tension induction, and impaired coping strategies in response to stress in women with PCOS correlate with clinical and laboratory indices of hyperandrogenism and not with central obesity and insulin resistance
- Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
- Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- HORMONAL IMPLANTS, BEAUTY CHIP; BENEFITS AND HARMFUL
- Comment on Current Investigations into the Postfinasteride Syndrome
- Male baldness and skin cancer: what are we missing in daily practice?
- Baghnakh (Martynia annua): Prehistory to contemporary medicinal value
- A Comment on Coronavirus Disease 2019 and the Hair
- Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata
- Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2
- Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata